Blog

May 4, 2016

Biogen haemophilia spin-out to develop gene therapies and long-acting factors

Posted by in categories: business, life extension

The new entity will focus on a haemophilia pipeline utilising the XTEN half-life extension technology, bispecific antibodies and gene therapies.

Biogen announced yesterday it is planning to spin-out its haemophilia business into an independent, public firm based in Boston, Massachusetts by early next year.

Management said during a conference call this was the right time for a spin-out as Biogen’s haemophilia business has matured.

Read more

1

Comment — comments are now closed.

  • Pankaj Nagar on May 18, 2016 7:02 am

    My son 6 years old have hemophilia A <1%